Aggregon Technology



XEME is dedicated to the development of innovative therapeutic cancer vaccine and other immune-oncology products. XEME innovated the personalized therapeutic cancer vaccine called Aggregon®, which is structured in multilamellar coalescence vesicles containing patient’s cancer cell and Interleukin-2 that activates the immune system in patients.

Aggregon® technology has the following competitive advantages for hematologic cancer and solid tumor:

  • indicated efficacy in previous clinical studies;
  • very low cost of production;
  • broad spectrum of potential clinical applications – personalized and off the shelf products;
  • rapid manufacturing process (less than 24 hours); and
  • relatively low cost per does, per patient.

Aggregon® Oncoquest is an autologous personalized therapeutic cancer vaccine. Aggregon® is structured in a form of multilamellar liposome, containing patient’s cancer cell and Interleukin-2. Aggregon® sustains immune effect for a long time and delivers Interleukin-2 to human immune cells non-toxicity. 

Aggregon® (off-the-shelf) is a non-autologous therapeutic cancer vaccine. In certain cancers, all patients have an antigen (TAA) that is identified identically. We are developing ready-to-use, off-the-shelf therapeutic Aggregon. It could lead to highly effective treatments that could be used in multiple patients, unlike current personalized treatments. The vaccine will be in a readymade form that can be sold commercially by injecting TAA into Aggregon® instead of patient’s cancer cells.

Aggregon® Oncolipin: In the case of solid cancer, it is difficult to activate immune cells due to poor lyse in the cancer microenvironment. Aggregon® Oncolipin vaccine is injected directly into Tumor using only MLCV + rhIL-2 without antigen to activate the immune cells. Cytokine is injected directly into Tumor cell (In Situ or Intratumoural) to aid in the activity of immune cells and dissolution of cancer cells.

Aggregon® Oncolipin with Oncolytic virus: As an extension model of Aggregon® Oncolipin, XEME is in process of developing a conjunction Aggregon with oncolytic virus. Oncolytic viruses are ideal platforms for tumor vaccination because they can mediate the direct in situ killing of tumor cells and reduce immune suppression in the tumor microenvironment.

For detailed information please visit https://www.xemebiopharma.com/. You can also contact us directly at info@r2tbio.com.